Oncology
Search text
Adolfo A. Ferrando M.D., Ph.D.
5 results
(0.02 seconds)
This technology is a bioengineered bone marrow system that can be applied to study various human diseases, toxicity responses, and immune functions in vitro.
This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells.
This technology is a murine model of angioimmunoblastic T-cell lymphoma with Rhoa G17V expression, which recapitulates the features of human disease for further study and therapeutic development.
This technology is a mouse model expressing the human oncogene T cell leukemia homeobox protein-1 (TLX1), which mimics the genetic and molecular signatures of T cell acute lymphoblastic leukemia (T-ALL).
This technology describes the synthesis and characterization of small molecule NT5C2 inhibitors for the treatment of relapsed and chemotherapy-resistant acute lymphoblastic leukemia (ALL) and T-cell acute lymphoblastic leukemia (T-ALL).